News and Trends 24 Jun 2020 Dutch VC Raises €105M to Nurture European Biotech Startups Biogeneration Ventures (BGV) has raised €105M for its fourth early-stage biotech fund, which aims to team up with academic institutions across Europe to create medical biotech companies. The fund, called BGV-IV, exceeded the amount the firm expected to raise. It attracted investors in previous funds back to the table such as the US big pharma […] June 24, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jun 2020 Belgian mRNA Vaccine for Covid-19 Receives €34M Series B Boost Belgian biotech eTheRNA has secured €34M in Series B funding to progress to the clinic its Covid-19 vaccine candidate and cancer immunotherapies made from messenger RNA. The company’s five existing investors contributed to the round, including Dutch VC firm LSP, and the Boehringer Ingelheim Venture Fund, based in Germany. Four new investors also contributed — […] June 18, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2020 German Government Invests €300M in mRNA Biotech CureVac The Federal Republic of Germany will invest €300M in CureVac, the homegrown biotech that is developing a vaccine for Covid-19 using messenger RNA technology. The unusually large investment will be made through the state-owned bank Kreditanstalt für Wiederaufbau, which will gain a 23% stake in the company. “CureVac retains complete operational and strategic independence,” Franz-Werner […] June 17, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2020 Novo Nordisk Foundation Commits €100M Grant to Developing Green Tech The Novo Nordisk Foundation has awarded a five-year grant of €100M to the DTU Biosustain research center near Copenhagen to support the development of sustainable green technology. DTU Biosustain was founded in 2011 and forms part of the Danish Technical University. The Novo Nordisk Foundation, which is one of the largest charitable foundations in the […] June 15, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2020 Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1B British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US big pharma Eli Lilly to develop RNA drugs that are delivered in exosomes to the brain to treat neurological diseases. As part of the deal, Evox will get €17.6M upfront to fund research for the next three years and Lilly […] June 11, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2020 Boost For Inflammatory Disease Biotech NodThera With €49M Series B The UK-US biotech NodThera has raised €48.7M in Series B funding to progress its drug candidate through clinical trials for the treatment of inflammatory conditions such as inflammatory bowel disease. This round follows an impressive €32M Series A that Nodthera carried out in 2018. Danish firm Novo Ventures, part of the investment arm of Novo […] June 6, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2020 Israeli-Dutch Biotech Raises €55M to Fight Huntington’s Disease and ALS Prilenia Therapeutics has raised €55M in Series A funding to launch late-stage clinical trials of its small molecule candidate drug in Huntington’s disease and amyotrophic lateral sclerosis, incurable conditions that have very limited treatment options. Dutch life sciences VC Forbion led the round and was joined by new Chinese investor Morningside Venture Investments and the […] June 5, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2020 Spanish Neurology Biotech Launches with €7.6M Series A Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […] May 29, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 28 May 2020 MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience The US-based big pharma MSD has entered the race to be the first to develop an effective vaccine for Covid-19 by acquiring Austrian biotech Themis Bioscience and its vaccine technology for an undisclosed amount. MSD has been a bit slower than some of its contemporaries to announce its plans regarding a potential treatment or vaccine […] May 28, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2020 ‘Just Add Water’ GM Mosquitoes Suppress Wild Population by 95% Water-soluble capsules containing the eggs of genetically modified mosquitoes developed by the UK company Oxitec have reduced the mosquito population in a dengue-infected urban environment in Brazil by 95% after 13 weeks. Aedes aegypti mosquitoes carry a number of infections including dengue, Zika, chikungunya, and yellow fever. Dengue has increased almost 15-fold over the last […] May 27, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 25 May 2020 Could Cell Therapy Target the Symptoms of Severe Covid-19? The excessive inflammatory response seen in the most serious cases of Covid-19, along with shortages of ventilators, has caused a healthcare crisis in many countries around the world. Could cell therapy provide an answer to this dilemma? Most people who become infected with Covid-19 experience symptoms such as a dry cough and mild fever, and […] May 25, 2020 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2020 Phase II Success for Once-a-Day Eye Drops after Cataract Surgery A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year for the company, which closed a €31M Series B fundraising round at the beginning of 2019. In February this year, Oculis also […] May 20, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email